報價延遲最少15分鐘:2025/06/03 23:02 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.65 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.35/-0.37
|
|
企業價值
405.64M
|
| 資產負債 |
|
每股賬面淨值
0.38
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.00M
|
|
每股收益
0.06
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/03 23:02 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its tworare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). |